| Ytd | 35.71% | |
| 1y | 93.44% |
| Open | 17.83 | Prev Close | 17.88 | Low | 17.07 | High | 18.00 | Mkt Cap | 5.46B |
| Vol | 0.00 | Avg Vol | 1.96M | EPS | 0.90 | P/E | 19.00 | Forward P/E | 15.12 |
| Beta | 1.25 | Short Ratio | 3.55 | Inst. Own | 53.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 16.74 | 200-d Avg | 13.73 | 1yr Est | 20.75 |
Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally stro
Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercializati
Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected
UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises th
Arkadios Wealth Advisors purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AM
Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the qua
Amneal Pharmaceuticals NASDAQ: AMRX reported second-quarter 2026 revenue of $796 million, up 10% fro
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks
Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2026 Adj EPS guidance from $0.95-$1.05 to $0.96-$1.06
Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.30 per share which beat the a
– Q2 2026 Net Revenue of $796 million ; GAAP Net Income of $58 million ; Diluted Income per Share o
Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up t
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AM
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t
Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/m
BRIDGEWATER, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“A
UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises th
BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“A
On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi
FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after recei
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significan
MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals tod
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc
https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-
3 health care stocks flashing warning: CAH RSI 77.7, TGTX RSI 79.8, AMRX RSI 76.9; all overbought, b
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a l
On June 10, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 4.4% today, bringing the current pri
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR New
Overall Interim Findings (Entire Study Population, 214Patients; Six-Week Analysis)All 214 patients w
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announc
Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight
Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars pla
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a diversifie
Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of C
UBS analyst Ashwani Verma initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy r
https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
Truist Securities analyst Les Sulewski maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy
Amneal beats fourth-quarter earnings and revenue estimates, driven by CREXONT sales, and guides up t
Amneal Pharmaceuticals (NASDAQ:AMRX) is looking for FY2026 Adj EPS of $0.93-$1.03 vs $0.94 analyst e
Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.21 per share which beat the a